Question
What is the expected intra-individual biological variability of PSA levels in elderly men over a 30-day period, and how often does this account for short-term increases like 5.7 → 6.7 ng/mL?
Answer
Short answer: Short-term, within-person PSA variation over days to weeks typically falls around ~7–20% (assay and population dependent). “Significant change” thresholds (reference change values, RCV) in controlled settings are often in the range of ~15–30% for increases, while thresholds derived from routine clinical practice can be higher (≈30–50%), reflecting added preanalytical noise. A rise from 5.7 to 6.7 ng/mL is a ~17.5% increase, which frequently lies within expected biological ± analytical variation—i.e., it may not indicate disease progression by itself.
How often is a short-term rise “just variability”? Large screening cohorts show that a meaningful fraction of newly elevated PSAs revert on repeat testing; for example, ~25–40% normalize upon retest in 6–8 weeks. Thus, month-to-month bumps of the magnitude above commonly reflect variability or transient factors rather than sustained progression.
Practical notes for a reliable re-check
- Repeat PSA in ~6–8 weeks before additional imaging/biomarkers, per major guidelines.
- Standardize pre-test conditions: avoid ejaculation for 48–72 h; defer testing after urinary instrumentation, acute urinary retention, vigorous cycling, fever/UTI, or prostatitis treatment; draw at the same lab/assay when possible.
Key references
- European Biological Variation Study (EuBIVAS): updated within-subject BV for PSA (~6.8%) with RCV for increase ≈15–20%. Clin Chim Acta, 2018.
- Meta-analyses/series reporting typical short-term PSA BV around ~13–20% over days–weeks: Eastham et al., JAMA, 2003; Christensson et al., 2010.
- AUA/SUO Early Detection Guideline: repeat a newly elevated PSA; 25–40% normalize on retesting; STHLM-3 8-week data cited. AUA/SUO 2023.
- Analytical imprecision for common PSA assays typically ~3–9%, contributing to RCV. Nixon et al., 1997.